Tests a once-weekly HIV pill combination in adults not yet treated
Tests islatravir and ulonivirine, taken weekly, against a daily standard HIV treatment.
Plain-language title generated from the registry record
Registry title: A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Key facts
- Where
- Buenos Aires, Caba, CABA, Mar del Plata, Rosario, and San Miguel de Tucumán, ArgentinaSee the 6 sites
- Phase
- Phase 2/3
Where in Argentina
- Fundación IDEAA (Site 3101)Buenos Aires, ArgentinaTaking people
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada (Site 3102)Caba, ArgentinaTaking people
- Fundación Huesped (Site 3100)CABA, ArgentinaTaking people
- Instituto de Investigaciones Clinicas Mar del Plata (Site 3103)Mar del Plata, ArgentinaTaking people
- Instituto CAICI SRL (Site 3106)Rosario, ArgentinaTaking people
- Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L (Site 3105)San Miguel de Tucumán, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT07266831EU 2025-522519-40-00
- Record updated
- 4 November 2026
- Original description
Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to learn: 1) If the study ART works as well as a standard ART to treat HIV-1, and 2) About the safety of the study ART and if people tolerate it compared to a standard ART.Read full original descriptionShow less
A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV-1
Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to learn: 1) If the study ART works as well as a standard ART to treat HIV-1, and 2) About the safety of the study ART and if people tolerate it compared to a standard ART.
Inclusion: Phase 2: Is human immunodeficiency virus type 1 (HIV-1) positive with Plasma HIV-1 ribonucleic acid (RNA) ≥500 and ≤100,000 copies/mL; Phase 3: Is HIV-1 positive with Plasma HIV-1 RNA ≥500 and ≤1,000,000 copies/mL; Phase 2: Has cluster of differentiation 4-positive (CD4+) T-cell count ≥200 cells/mm\^3; Is naïve to antiretroviral therapy (ART), defined as having received no prior therapy with any antiretroviral agent following a diagnosis of HIV 1 infection.
Exclusion: Has prior exposure to islatravir (ISL) or ulonivirine (ULO) for any duration any time prior to Day 1; Has human immunodeficiency virus type 2 (HIV-2) infection; Has a diagnosis of an active acquired immune deficiency syndrome (AIDS)-defining opportunistic infection; Has active hepatitis C virus (HCV) or active hepatitis B virus (HBV) infection; Has a history of malignancy ≤5 years prior to providing documented informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical or in situ anal cancer, or cutaneous Kaposi's sarcoma.